Clinical trial
Omalizumab to Treat Eosinophilic Gastroenteritis
NCT00084097 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00084097 |
|---|---|
| Title | Omalizumab to Treat Eosinophilic Gastroenteritis |
| Official title | Pilot Study of Omalizumab in Eosinophilic Gastroenteritis |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastroenteritis |
| Intervention type | Drug |
| Interventions | Omalizumab |
| Enrollment | 30 |
| Start date | Jun 2, 2004 |
| Completion | Feb 5, 2007 |
| First posted | Jun 7, 2004 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: